GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » 3-Year FCF Growth Rate

Titan Pharmaceuticals (FRA:TN70) 3-Year FCF Growth Rate : 53.50% (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals 3-Year FCF Growth Rate?

Titan Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was €-2.73.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 53.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 63.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Titan Pharmaceuticals was 74.50% per year. The lowest was -39.40% per year. And the median was 14.50% per year.


Competitive Comparison of Titan Pharmaceuticals's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Titan Pharmaceuticals's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Titan Pharmaceuticals's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Pharmaceuticals's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Titan Pharmaceuticals's 3-Year FCF Growth Rate falls into.



Titan Pharmaceuticals 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Titan Pharmaceuticals  (FRA:TN70) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Titan Pharmaceuticals 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Titan Pharmaceuticals (FRA:TN70) Business Description

Traded in Other Exchanges
Address
400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080
Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines